e262 Abstracts / Digestive and Liver Disease 51 (2019) e259–e264 1. Only 2/275 patients have formally requested for a on-treatment medical consultation, and 35/275 requested a brief interview with either a physician or a nurse. No statistically significant differences were observed between patient that had requested an interview or additional visit (group 1), and patients who did not (group 2). The SVR rate was 97.9% (97.5% in group 2). With the Simplified on-treatment schedule we avoided 1012 visits, 253 working- hours for the physician and the loss of 3,68 working-days for patient. Conclusions: The adoption of the short schedule during the DAA-therapy allowed unmodified high SVR12 rates (97.5%) with the advantage of avoiding unnecessary visits, saving time and money (that we can use to treat more patients) and working days of the patient with further saving for the society. https://doi.org/10.1016/j.dld.2019.08.007 P-07 Current epidemiology of HCV in Sicily: the RESIST-HCV model V. Di Marco 1,3 , F. Cartabellotta 3 , W. Mazzucco 2 , V. Calvaruso 1 , S. Petta 1 , S. Mazzola 2 , R. Cusimano 2 , R. Amodio 2 , G. Scifo 3 , M. Russello 3 , B. Cacopardo 3 , G. Squadrito 3 , G. Raimondo 3 , T. Pollicino 4 , F. Ceccherini-Silbertein 4 , F. Vitale 2 , C. Cammà 1 , A. Craxì 1,3 , on behalf of RESIST-HCV 1 UOC di Gastroenterologia e Epatologia, AOUP Palermo 2 UOC di Epidemiologia Clinica con Registro Tumori, AOUP Palermo 3 Rete Sicilia Selezione Terapia HCV (RESIST-HCV) Scientific Committee 4 HCV Virology Italian Resistance Network (VIRONET-C) Background: Real-world data to guide hepatitis C virus (HCV)- related public health initiatives and linkage to care of patients are lacking in our region. Aims: To describe the epidemiological features of a large cohort of patients with chronic HCV infection from Sicily included in a regional network aimed at DAA treatment (RESIST-HCV). Methods: Demographic and clinical data were recorded on a web-based platform before starting treatment with DAAs. Gender, year of birth, HCV genotype, co-infections, stages of liver disease and co-morbidities were analyzed. Chi-square with Yates correc- tion was appliedto assess the differences between cohorts. Results: Overall, 15,270 patients were registered on the HCV- RESIST platform from March 2015 to March 2019. The analysis of demographic and viral features showed a clear-cut bimodal distribution, defining two cohorts of patients. The first (cohort 1) includes 9.939 patients (65%) born between the years 1930 and 1959, while the second (cohort 2) included 5.331 patients (35%) born between 1960 and 1999. When comparing the two cohorts, cohort 1 had a higher rate of infection with HCV Gt 1b or 2 (90% vs 47%; p < 0.0001), higher rate of cirrhosis (49.5% vs 37.5% in cohort 2; p < 0.001), hepatocellular carcinoma (3.3% vs 0.6%; p < 0.0001), diabetes (26.8% vs 10.3%; p < 0.0001) and of arterial hypertension (50.4% vs 13.5%; p < 0.0001). By converse, in cohort 2 there was a higher proportion of males (71.3% vs 48.7%; p < 0.0001), subjects naïve to IFN-based treatment (66.2% vs 62.5%; p < 0.0001), infection with HCV Gt 1a, 3 or 4 (53% vs 10%; p < 0.0001), HIV co-infection (7.8% vs 1%; p < 0.0001), and PWIDs(12% vs 1%; p < 0.0001). Conclusions: In Sicily, a region where HCV is still endemic, chronic HCV infection has a bimodal distribution, with two dif- ferent cohorts affected. One cohort reflects a first epidemic wave, mostly fueled by Gt 1b and 2, through unsafe medical prac- tices and non-sexual intrafamilial spreading between 1940 and 1990. About half of these patients has developed cirrhosis and many have co-morbidities that may worsen the prognosis. Another cohort originated between 1970 and 2000 mostly through nee- dle sharing and unsafe sex, thus frequently associating with HIV, and is sustained mostly by Gt1a and 3. In order to reach the WHO elimination targets by 2020, graduated screening poli- cies according to this mode of distribution of HCV should be devised. https://doi.org/10.1016/j.dld.2019.08.008 P-08 Second-generation DAAs for HCV: real-life efficacy in the RESIST-HCV cohort I. Cacciola 1 , S. Petta 1 , V. Calvaruso 1 , F. Cartabellotta 1 , M. Distefano 1 , G. Scifo 1 , F. Di Lorenzo 1 , A. Sanfilippo 1 , M.A. Di Rosolini 1 , A. Davì 1 , F. Benanti 1 , B. Cacopardo 1 , A. Licata 1 , L. Giannitrapani 1 , M.R. Cannavò 1 , M. Russello 1 , S. Madonia 1 , M.G. Bavetta 1 , A. Digiacomo 1 , A. Averna 1 , G. Alaimo 1 , L. Larocca 1 , G. Bertino 1 , F. Bronte 1 , L. Guarneri 1 , I. Scalisi 1 , C. Iacobello 1 , P. Colletti 1 , V. Portelli 1 , T. Pollicino 2 , F. Ceccherini-Silberstein 2 , G. Raimondo 1 , A. Craxì 1 , V. Di Marco 1 , on behalf of RESIST-HCV 1 Rete Sicilia Selezione Terapia – HCV (RESIST-HCV) 2 HCV Virology Italian Resistance Network (VIRONET-C) Background and aims: RESIST-HCV (Rete Sicilia Selezione Ter- apia – HCV) registers all patients in Sicily with chronic HCV infec- tion treated with DAAs, allowing a real-time measure of their effi- cacy in practice. This analysis aims to evaluate second-generation regimens (Sofosbuvir plus Velpatasvir: SOF/VEL; Glecaprevir plus Pibrentasvir: GLE/PIB;Elbasvir/Grazoprevir: EBV/GRZ), in order to evaluate SVR rates of DAA-naïve patients to currently available regimens. Methods: We analyzed 4,087 patients who received treatment between March 2017 and December 2018 whose SVR12 data were available in the RESIST-HCV database by June 2019. Cirrhosis was diagnosed by liver stiffness 3 12 KPa (Fibroscan) and/or by presence of esophageal varices at endoscopy and/or by a liver biopsy with METAVIR stage 4 fibrosis. Results: By ITT analysis 95.1% of patients (3,878/4,078) achieved SVR. Overall, 125 patients (3.1%) did not complete the assigned therapy. Of them, 11 patients (0.3%) died for liver-related (5 patients) or unrelated (6 patients) causes while on treatment. Twenty patients (0.5%) discontinued treatment due to adverse events and 94 patients (2.2%) did not have virology available at end of therapy (ETR) or for SVR evaluation. Seventy-five patients (1.8%) did not achieve SVR: of them, 14 were still HCV-RNA pos- itive at the end of therapy and 61 showed a virological relapse after ETR. By PP analysis 98.1% of patients (3878/3953) obtained an SVR. The rates of PP SVR according to HCV genotype (Gt) and stage of disease are reported Table 1. Patients with chronic hepati- tis and Gt 1a, 1b, 2 or 4 obtained SVR rates higher than 99% when treated with pangenotypic regimes (SOF/VEL or GLE/PIB). SVR rates above 96% were obtained in patients with cirrhosis and Gt 1a, 1b, 2 or 4 treated with SOF/VEL or GLE/PIB. Adding ribavirin to SOF /